RHAMM can also bind directly to CD44 at the plasma membrane, and activate CD44 signaling through ERK1/2, potentially enhancing cancer cell migration [89], and indicating the collaboration of different receptors to activate signaling pathways. Here, CD44 is linked to cancer.